Moleculin Biotech (Nasdaq:MBRX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MBRX 주식 개요

임상 단계의 제약 회사인 몰큘린 바이오텍은 암과 바이러스 치료를 위한 신약 후보 물질 개발에 주력하고 있습니다.

MBRX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

위험 분석

cash runway 경력이 1년 미만입니다.

수익이 1백만 달러 미만인 경우 ( $0 )

의미 있는 시가총액이 없습니다. ( $9M )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 2 더 많은 위험

Moleculin Biotech, Inc. 경쟁사

Biodexa Pharmaceuticals

NasdaqCM:BDRX

US$9.5m

ABVC BioPharma

NasdaqCM:ABVC

US$7.8m

Inhibikase Therapeutics

NasdaqCM:IKT

US$10.8m

Enzon Pharmaceuticals

OTCPK:ENZN

US$11.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Moleculin Biotech
과거 주가
현재 주가	US$3.78
52주 최고치	US$15.75
52주 최저치	US$3.75
베타	1.86
11개월 변경	-23.79%
3개월 변경 사항	-33.74%
1년 변경 사항	-57.99%
33년 변화	-93.45%
5년 변화	-96.56%
IPO 이후 변화	-99.48%

최근 뉴스 및 업데이트

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jan 15

Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas

Dec 29

Moleculin Bio on go with mid-stage study of Annamycin for lung metastases

Dec 17

Moleculin Biotech's annamycin shows encouraging action in animal study

Nov 19

Moleculin Biotech EPS beats by $0.04

Nov 13

Moleculin further collaborates to advance WP1122 in COVID-19

Oct 29

주주 수익률

	MBRX	US Biotechs	US 마켓
7D	-13.1%	-1.3%	0.4%
1Y	-58.0%	7.7%	22.9%

수익률 대 산업: MBRX 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: MBRX 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is MBRX's price volatile compared to industry and market?
MBRX volatility
MBRX Average Weekly Movement	11.7%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: MBRX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: MBRX 의 주간 변동성( 13% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2015	18	Wally Klemp	moleculin.com

임상 단계 제약 회사인 몰큘린 바이오텍은 암과 바이러스 치료를 위한 신약 후보 물질 개발에 주력하고 있습니다. 주요 약물 후보로는 재발성 또는 불응성 급성 골수성 백혈병(AML) 및 폐로 전이된 연조직 육종 치료를 위한 1B/2상 임상시험 중인 Annamycin이 있습니다. 또한 뇌종양, 췌장암 및 기타 암을 표적으로 하는 인산화 신호 전달체 및 전사인자 및 기타 발암성 전사인자를 억제하도록 설계된 면역/전사 조절제인 WP1066을 개발 중입니다.

Moleculin Biotech, Inc. 기본 사항 요약

Moleculin Biotech 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MBRX 기본 통계
시가총액	US$9.20m
수익(TTM)	-US$26.82m
수익(TTM)	n/a

0.0x

P/S 비율

-0.3x

P/E 비율

MBRX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MBRX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$26.82m
수익	-US$26.82m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-11.60
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

MBRX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

MBRX 주식 개요

보상

위험 분석

Moleculin Biotech, Inc. 경쟁사

NasdaqCM:BDRX

US$9.5m

NasdaqCM:ABVC

US$7.8m

NasdaqCM:IKT

US$10.8m

OTCPK:ENZN

US$11.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

Recent updates

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

New major risk - Share price stability

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

New major risk - Share price stability

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Price target decreased to US$8.67

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Price target decreased to US$11.67

Price target increased to US$21.50

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Moleculin Biotech, Inc. Receives IND Clearance to Conduct Phase 1 Study of WP1066 for Treatment of Recurrent Malignant Glioma

Moleculin Biotech, Inc., Annual General Meeting, May 26, 2022

Moleculin Biotech, Inc. Announces Presentation of Positive Preclinical Annamycin Data At the AACR 2022 Annual Meeting

We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth